Genome editing by programmed deaminases

KeyGene reference: P200

Invention

The invention relates to genome editing using cysteine or adenine deaminase fused to a site-specific nuclease such as an RNA-guided CRISPR-CAS protein. These fusion proteins allow the precise conversion of single nucleotides in single targeted locus of the genome. Using a combination of two fusion proteins effectively directs the simultaneous conversion of both a cytosine and an adenine in a single locus.

Benefit

Genome editing technologies are rapidly emerging. The present invention allows for a highly precise orchestration of nucleotide conversions. The fusion proteins of the invention, and combined working thereof, contribute to the endless options of nucleotide changes that can be achieved with available genome editing tools.

Vision

Understanding the function of genes is essential for efficient breeding of improved crops. Efficient targeted genome editing technologies are important research tools in gene validation and may be used for introduction of new traits in crop germplasm. The present invention contributes thereto.

Patent

Click on the link for an overview of the patent family in the European Patent Register: WO2018/149915

Please note that the European Patent Register may not be extensive and/or accurate, for which KeyGene is not responsible. Please contact your patent expert for further information.

Would you like to explore the possibilities for obtaining a license for this technology? You can contact our licensing team by mail.

Would you like to know more about our technologies and licensing possibilities? Visit our webpage about Licensing KeyGene’s proprietary technologies.